SCHEMBL6154422

SCHEMBL6154422

N#Cc1ccc(OC2CCC(N3C(=O)c4ccccc4C3=O)CC2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 7/20 0.46
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
PGR P06401 2/20 0.39
KDM1A O60341 1/20 0.39
ALK Q9UM73 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE9A O76083 1/20 0.38
MAOA P21397 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
STAT3 P40763 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16997532 0.79 KMT2A (0.54) TSHRKMT2AMAOAL3MBTL1
SCHEMBL1063449 0.79 KMT2A (0.54) TSHRKMT2AMAOAL3MBTL1
SCHEMBL1060544 0.79 KMT2A (0.54) TSHRKMT2AMAOAL3MBTL1
SCHEMBL1060542 0.79 KMT2A (0.54) TSHRKMT2AMAOAL3MBTL1
SCHEMBL12931837 0.76 EPHX2 (0.49) SLC6A2SLC6A4SLC6A3TSHRKMT2A
SCHEMBL18855674 0.76 TRPV4 (0.48) TRPV4PGRALK
SCHEMBL18809479 0.75 L3MBTL1 (0.52) SLC6A2SLC6A3TSHRKMT2AL3MBTL1
SCHEMBL24299380 0.73 ACSL1 (0.46) TRPV4PGR
SCHEMBL24298603 0.73 ACSL1 (0.46) TRPV4PGR
SCHEMBL22565215 0.71 AR (0.45) PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 TRPV4 387/4885SLC6A2 337/4885SLC6A4 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.